Orbital Therapeutics, a well-funded biotech born out of buzzy base editing company Beam Therapeutics, has shuttered its South San Francisco office.
The startup was unveiled in April with a $270 million Series A from ARCH Venture Partners, a16z Bio + Health, and more than half a dozen other investors….
Click here to view original post
